Cardiotonic steroids on the road to anti-cancer therapy

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• The sodium pump (Na(+)/K(+)-ATPase) is crucial in cell signaling and adhesion, with aberrant expression linked to cancer development.
• Cardiotonic steroids, known sodium pump ligands used for heart failure, exhibit anti-cancer properties in preclinical studies.
• Developing cardiotonic steroids as anti-cancer agents is hindered by their narrow therapeutic index and potential cardiovascular toxicity.

Purpose of the Study:

• To review the structure, function, and cancer-related targeting of the sodium pump.
• To summarize the in vitro and in vivo anti-cancer activities of cardiotonic steroids.
• To discuss strategies for managing cardiotonic steroid toxicity and improving their anti-cancer efficacy through chemical modification.

Main Methods:

• Literature review of sodium pump function, cancer expression, and cardiotonic steroid activity.
• Analysis of preclinical and clinical data on cardiotonic steroids as anti-cancer agents.
• Evaluation of toxicity management and predictive models for cardiotoxicity.

Main Results:

• Sodium pump dysregulation is implicated in various cancers, making it a viable therapeutic target.
• Cardiotonic steroids demonstrate significant anti-cancer effects, but cardiovascular side effects limit clinical application.
• Current preclinical models have limitations in predicting human cardiotoxicity.

Conclusions:

• Targeting the sodium pump with cardiotonic steroids offers a promising avenue for cancer therapy.
• Mitigating cardiovascular toxicity through chemical modification is essential for advancing these compounds in oncology.
• Further research is needed to refine predictive models and develop safer, more effective cardiotonic steroid-based chemotherapeutics.